Prohance and Visual acuity reduced transiently - a phase IV clinical study of FDA data
Visual acuity reduced transiently is reported only by a few people who take Prohance.
The phase IV clinical study analyzes which people take Prohance and have Visual acuity reduced transiently. It is created by eHealthMe based on reports of 3,617 people who have side effects while taking Prohance from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
3,617 people reported to have side effects when taking Prohance.
Among them, 2 people (0.06%) have Visual acuity reduced transiently.
What is Prohance?
Prohance has active ingredients of gadoteridol. eHealthMe is studying from 3,618 Prohance users for its effectiveness, alternative drugs and more.
What is Visual acuity reduced transiently?
Visual acuity reduced transiently is found to be associated with 198 drugs and 98 conditions by eHealthMe.
Number of Prohance and Visual acuity reduced transiently reports submitted per year:
Time on Prohance when people have Visual acuity reduced transiently *:
- < 1 month: 100 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Visual acuity reduced transiently when taking Prohance *:
- female: 100 %
- male: 0.0 %
Common side effects people have besides Visual acuity reduced transiently *:
- Weakness: 2 people, 100.00%
- Nausea (feeling of having an urge to vomit): 2 people, 100.00%
- Hyperhidrosis (abnormally increased sweating): 2 people, 100.00%
- Haematochezia (passage of stools containing blood): 2 people, 100.00%
- Diarrhea Haemorrhagic: 2 people, 100.00%
* Approximation only. Some reports may have incomplete information.
Do you take Prohance and have Visual acuity reduced transiently?Check whether Visual acuity reduced transiently is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Visual acuity reduced transiently and when was it recovered:
Expand to all the drugs that have ingredients of gadoteridol:
Alternative drugs to, pros and cons of Prohance:
- Prohance (3,618 reports)
Common Prohance side effects:
- Pain: 1,520 reports
- Stress and anxiety: 887 reports
Browse all side effects of Prohance:a b c d e f g h i j k l m n o p q r s t u v w x y z
Visual acuity reduced transiently treatments and more:
- Visual acuity reduced transiently (310 reports)
COVID vaccines that are related to Visual acuity reduced transiently:
- Visual acuity reduced transiently in Moderna COVID Vaccine
- Visual acuity reduced transiently in Pfizer BioNTech Covid Vaccine
- Visual acuity reduced transiently in Johnson and Johnson Covid Vaccine
All the drugs that are associated with Visual acuity reduced transiently:
- Visual acuity reduced transiently (198 drugs)
All the conditions that are associated with Visual acuity reduced transiently:
- Visual acuity reduced transiently (98 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on gadoteridol (the active ingredients of Prohance) and Prohance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Trigeminal Neuralgia in Fosamax, how severe and when it was recovered? - 3 seconds ago
- Diazepam and Blood Myoglobin Increased - 12 seconds ago
- Fosamax and Migraine With Aura - 14 seconds ago
- Abreva and Actos drug interaction - 24 seconds ago
- Aranesp and Irritable Bowel Syndrome - 27 seconds ago
- Allergic Rhinitis and Type 1 Diabetes - 30 seconds ago
- Transderm Scop and Overdose - 32 seconds ago
- Depo-Medrol and Tricuspid Valve Incompetence - 39 seconds ago
- Remicade and Methylprednisolone drug interaction - 42 seconds ago
- Betamethasone Dipropionate and Foetal Exposure During Pregnancy - 46 seconds ago